‘End of the war is in sight’ — Cramer says Dr. Gottlieb’s end-of-pandemic call bigger than jobs data

- Advertisement -


  • CNBC’s Jim Cramer on Friday eased Dr. Scott Gottlieb’s prediction that the pandemic phase of COVID could be over by January.
  • “Dr Gottlieb basically said the war is over, and that’s unbelievable,” Kramer said.
  • “I don’t even care about the employment numbers – the pandemic is over,” Cramer said. “Looks like it’s over.”

- Advertisement -

CNBC’s Jim Cramer on Friday eased Dr. Scott Gottlieb’s prediction that the pandemic phase of COVID could be over by January.

- Advertisement -

“Dr Gottlieb basically said the war is over, and that’s unbelievable,” Kramer said. Gottlieb, who served as FDA chief under former President Donald Trump, is currently a member of the Pfizer board.

“By January 4th, this pandemic may well be over, at least concerning the United States, after we go through this delta wave of infections,” Gottlieb said on “Squawk Box.” After that “we will be in a more spatial phase”.

- Advertisement -

Gottlieb referred to January 4 as the new deadline for the Biden administration’s mandate for large US companies to ensure their employees are fully vaccinated or routinely tested for COVID-19. Is.

“The end of the war is in sight,” Cramer said.

The “Mad Money” host said Gottlieb’s comments Friday morning on CNBC were more important than the strong October jobs numbers.

“They were talking about employment, I don’t even care about employment numbers – the pandemic is over,” Cramer said. “Looks like it’s over.”

“Today is a good day,” Cramer said, referring to Pfizer’s announcement that internal data showed its oral COVID pill – when administered with a widely used HIV drug – could lead to hospitalization or death in adults. Indicated an 89% reduction in risk of Came in contact with coronavirus. Shares of Pfizer were up more than 8% on Friday morning.

“The only people who are unhappy are people who have stock that you need to be in,” Cramer said. Stocks advanced on Friday morning at the so-called economic reopening, while stay-at-home names came under pressure.

CNBC Health & Science

Read CNBC’s latest global coverage of the COVID pandemic:

Pfizer CEO says boosters needed to break virus cycle even with Kovid vaccine, effective pills

Pfizer says its COVID pill with HIV drug reduces the risk of hospitalization or death by 89%

WHO warns that Europe is once again at the center of the Kovid epidemic

Businesses have until after the holidays to implement Biden’s Covid vaccine mandate

Moderna shares fall after company cuts 2021 forecast for Covid vaccine sales

Merck’s antiviral COVID pill, developed with Ridgeback Biotherapeutics, was shown to reduce the risk of hospitalization and death from Covid by 50%, according to internal data released early last month. Shares of Merck were down about 9% on Friday, with the company facing competition in treatments.

Unlike Pfizer, Merck does not have a COVID vaccine.

Disclosure: Scott Gottlieb is a CNBC contributor and a member of the board of Pfizer, genetic testing start-up Tempus, health-care tech company Etion and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings and Royal Caribbean’s “Healthy Sail Panel”.

.

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox